Joyce A. O’Shaughnessy, MD
Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer (TNBC), but recent studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.
and O’Shaughnessy said she has used that drug with good results in an AR-positive breast cancer patient who had a low Ki67 level.
Recent Clinical Trials
Although some recent trials have been negative where TNBC is concerned, others that hold more promise are moving forward, O’Shaughnessy said.
“Intensive biomarker analyses are ongoing, including VEGF-A and VEGFR, but there’s no clear biomarker now that a subset benefits,” O’Shaughnessy said.
Molecular Snapshot of Triple-Negative Breast Cancer (TNBC)1
... to read the full story